Efficacy of Sodium Glucose Transporter Inhibitor (SGLT2i) in Adult Patients with Congenital Heart Disease
Latest Information Update: 10 Dec 2024
At a glance
- Drugs Empagliflozin (Primary)
- Indications Congenital heart defects; Heart failure
- Focus Therapeutic Use
- Acronyms EmpaCHD
Most Recent Events
- 19 Sep 2024 Planned initiation date (estimated date of first participant enrollement) changed from 1 Sep 2024 to 1 Oct 2024.
- 02 Aug 2024 Planned initiation date changed from 1 Feb 2024 to 1 Sep 2024.
- 02 Aug 2024 Status changed from not yet recruiting to recruiting.